The Role of Finerenone in the Management of Diabetic Nephropathy

Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Frömter Rats, a Genetic Model of Chronic Kidney Disease

(2020) Marta Gil-Ortega et al.   AMERICAN JOURNAL OF NEPHROLOGY

Results from Drug–Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications

(2020) Roland Heinig et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets

(2020) Jonatan Barrera‐Chimal et al.   DIABETES OBESITY & METABOLISM

The novel non‐steroidal MR antagonist finerenone improves metabolic parameters in high‐fat diet‐fed mice and activates brown adipose tissue via AMPK‐ATGL pathway

(2020) Vincenzo Marzolla et al.   FASEB JOURNAL

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

(2020) Rajiv Agarwal et al.   EUROPEAN HEART JOURNAL

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

(2020) George L. Bakris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone

(2020) Juan Simon Rico-Mesa et al.   Current Cardiology Reports

Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

(2020) Gerasimos Filippatos et al.   CIRCULATION

11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021

(2020)   DIABETES CARE

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment

(2019) Roland Heinig et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling

(2019) Daniel Lavall et al.   BIOCHEMICAL PHARMACOLOGY

Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta‐analysis

(2019) Chao Zuo et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction

(2018) Marianne Lachaux et al.   DIABETES OBESITY & METABOLISM

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance

(2018) Jana Grune et al.   HYPERTENSION

Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice

(2018) Benjamin Bonnard et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling

(2018) Jonatan Barrera-Chimal et al.   KIDNEY INTERNATIONAL

Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives

(2018) Peter Rossing et al.   Nephrologie & Therapeutique

Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro

(2018) Michael Gerisch et al.   DRUG METABOLISM AND DISPOSITION

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress

(2018) Raquel González-Blázquez et al.   Frontiers in Pharmacology

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance

(2017) Lionel Lattenist et al.   HYPERTENSION

A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy

(2017) Shigehiro Katayama et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1

(2017) Jonatan Barrera-Chimal et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

(2017) Lennart Tonneijck et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Avenues

(2017) Sebastian Oltean et al.   Biomed Research International

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

(2016) Gerasimos Filippatos et al.   EUROPEAN HEART JOURNAL

Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies

(2016) Silvia Lentini et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Natural History and Clinical Characteristics of CKD in Type 1 and Type 2 Diabetes Mellitus

(2014) Sally M. Marshall   ADVANCES IN CHRONIC KIDNEY DISEASE

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

(2014) Peter Kolkhof et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

(2013) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update

(2013) Mandeep Kumar Arora et al.   VASCULAR PHARMACOLOGY